Role of Endoplasmic Reticulum Stress in the Pathophysiology of Type 2 Diabetes (GLUCOSTRESS)

Assistance Publique - Hôpitaux de Paris

Status: Unknown

Conditions: Endoplasmic Reticulum Stress; Diabetes Mellitus, Type 2

Treatments: Other: No intervention

Study type: Observational

Funder types: Other

Identifiers

NCT02368704

GLUCOSTRESS P 08 11 22

Details and patient eligibility

About

The purpose of this study is to investigate whether Endoplasmic Reticulum (ER) stress pathway is activated in peripheral tissues (adipose tissue) in insulin resistant diabetic patients compared to healthy subjects normoglycemic matched for age and sex an to investigate whether ER stress pathway can be activated in response to insulin. Indeed, some preliminar on rates studies shows that ER stress pathway is activated by insulin in liver and adipose tissue showing that hyperinsulinemia might help trigger stress path ER.

For this, we propose a case control study of type 2 diabetic patients vs control subjects in which markers of ER stress will be evaluated from abdominal subcutaneous adipose tissue obtained before and after euglycemic hyperinsulinemic. We chose to consider adipose tissue subcutaneous rather than visceral adipose tissue for obvious reasons of lesser invasiveness.

Enrollment: 40 patients

Sex: All

Ages: 18 to 60 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Specific criteria for diabetic patients:
• Having type 2 diabetes for at least 6 months
• HbA1c ≤ 8%
• Treated by lifestyle and dietary rules associated or not to a hypoglycemic therapy (metformin and / or sulfamid) and / or insulin secretors dependent glucose as inhibitors of DPP4 (dipeptidyl peptidase-4): Vildagliptin, Sitagliptin, Saxagliptin
• No modification of hypoglycemic therapy and / or insulin secretors for at least 3 months

Specific criteria for control subjects:

• Nondiabetic subjects (fasting blood glucose <7.0 mmol / l without hypoglycemic treatment).
• The control subjects should be matched to patients for age (± 5 years), sex, and BMI (± 2 kg/m2).

Common criteria for patients and control subjects:

• Aged 18 to 60 years
• Body Mass Index between 25 and 35 kg/m2
• Accepting the constraints of the protocol and who signed the informed consent
• Systolic blood pressure < 160 mmHg, diastolic blood pressure < 90 mm Hg (with or without antihypertensive treatment)
• Resting heart rate between 55 and 100 beats/min.
• Normal laboratory tests or not clinically significant abnormality for NFS platelets, PT, aPTT, fibrinogen ALT, AST, GGT, Serum electrolytes, urea, creatinine, Uric acid Triglycerides, total cholesterol, HDL cholesterol
• HCG negative blood (for female subjects)
• Affiliated to the Social Security.

Exclusion criteria

• Current infections or recent infections (<10 days)
• Neoplastic disorders (with the exception of carcinoma in situ of the cervix or cutaneous epithelioma), haematological, cardiovascular, psychiatric, neurological
• Poisoning smoking (>10 cigarettes per day, what ever the duration of intoxication)
• Treatment with insulin or glitazones Pregnancy, Breastfeeding
• Body Mass Index > 35 kg/m2
• Any drug taken for less than 8 days without the inclusion of minor analgesics (aspirin, paracetamol), anti-hypertensive medications, oral hypoglycemic (metformin and sulphonylureas) and insulin secretors dependent glucose as inhibitors of DPP4 (dipeptidyl peptidase-4) and oral contraceptives.

Trial design

40 participants in 2 patient groups

control

Description:

control subjects with : * Nondiabetic subjects (blood glucose \<7.0 mmol/l without hypoglycemic treatment). * The control subjects should be matched to patients for age (± 5 years), sex, and BMI (± 2 kg/m2).

Treatment:

Other: No intervention

case

Description:

Diabetic patients with : * Having type 2 diabetes for at least 6 months * HbA1c ≤ 8% * Treat by lifestyle and dietary rules associated or not to a hypoglycemic therapy (metformin and / or sulfamid) and / or insulin secretors dependent glucose as inhibitors of DPP4 (dipeptidyl peptidase-4): Vildagliptin, Sitagliptin, Saxagliptin * No modification of hypoglycemic therapy and / or insulin secretors for at least 3 months

Treatment:

Other: No intervention